Asemi Zatollah, Samimi Mansooreh, Siavashani Mehrnush Amiri, Mazloomi Maryam, Tabassi Zohreh, Karamali Maryam, Jamilian Mehri, Esmaillzadeh Ahmad
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Int J Prev Med. 2016 Mar 1;7:49. doi: 10.4103/2008-7802.177895. eCollection 2016.
Pregnancy is associated with unfavorable metabolic profile, which might in turn result in adverse pregnancy outcomes. The current study was designed to evaluate the effects of calcium plus Vitamin D administration on metabolic status and pregnancy outcomes in healthy pregnant women.
This randomized double-blind placebo-controlled clinical trial was performed among 42 pregnant women aged 18-40 years who were at week 25 of gestation. Subjects were randomly allocated to consume either 500 mg calcium-200 IU cholecalciferol supplements (n = 21) or placebo (n = 21) for 9 weeks. Blood samples were obtained at the onset of the study and after 9-week trial to determine related markers. Post-delivery, the newborn's weight, length, and head circumference were measured during the first 24 h after birth.
Consumption of calcium-Vitamin D co-supplements resulted in a significant reduction of serum high-sensitivity C-reactive protein levels compared with placebo (-1856.8 ± 2657.7 vs. 707.1 ± 3139.4 μg/mL, P = 0.006). We also found a significant elevation of plasma total antioxidant capacity (89.3 ± 118.0 vs. -9.4 ± 164.9 mmol/L, P = 0.03), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. -1.7 ± 1.7 ng/mL, P < 0.0001), and calcium levels (0.6 ± 0.6 vs. -0.1 ± 0.4 mg/dL, P < 0.0001). The supplementation led to a significant decrease in diastolic blood pressure (-1.9 ± 8.3 vs. 3.1 ± 5.2 mmHg, P = 0.02) compared with placebo. No significant effect of calcium-Vitamin D co-supplements was seen on other metabolic profiles. We saw no significant change of the co-supplementation on pregnancy outcomes as well.
Although calcium-Vitamin D co-supplementation for 9 weeks in pregnant women resulted in improved metabolic profiles, it did not affect pregnancy outcomes.
妊娠与不良代谢状况相关，这反过来可能导致不良妊娠结局。本研究旨在评估补充钙加维生素D对健康孕妇代谢状况和妊娠结局的影响。
本随机双盲安慰剂对照临床试验在42名年龄在18 - 40岁、妊娠25周的孕妇中进行。受试者被随机分配服用500毫克钙 - 200国际单位胆钙化醇补充剂（n = 21）或安慰剂（n = 21），为期9周。在研究开始时和9周试验后采集血样以测定相关指标。分娩后，在出生后的头24小时内测量新生儿的体重、身长和头围。
与安慰剂相比，补充钙 - 维生素D导致血清高敏C反应蛋白水平显著降低（-1856.8 ± 2657.7 vs. 707.1 ± 3139.4 μg/mL，P = 0.006）。我们还发现血浆总抗氧化能力显著升高（89.3 ± 118.0 vs. -9.4 ± 164.9 mmol/L，P = 0.03）、血清25 - 羟基维生素D（2.5 ± 3.5 vs. -1.7 ± 1.7 ng/mL，P < 0.0001）和钙水平（0.6 ± 0.6 vs. -0.1 ± 0.4 mg/dL，P < 0.0001）。与安慰剂相比，补充剂导致舒张压显著降低（-1.9 ± 8.3 vs. 3.1 ± 5.2 mmHg，P = 0.02）。钙 - 维生素D联合补充剂对其他代谢指标无显著影响。我们也未发现联合补充剂对妊娠结局有显著改变。
尽管孕妇补充钙 - 维生素D 9周可改善代谢状况，但并未影响妊娠结局。
